EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity
Authors
Keywords
-
Journal
Future Oncology
Volume 8, Issue 8, Pages 1015-1029
Publisher
Future Medicine Ltd
Online
2012-08-16
DOI
10.2217/fon.12.89
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer
- (2012) Geoffrey Liu et al. Journal of Thoracic Oncology
- Association ofABCB1polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer
- (2012) Akinobu Hamada et al. PHARMACOGENOMICS
- DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma
- (2011) Ji-Youn Han et al. CANCER
- Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice
- (2011) Elisa Giovannetti et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Thymidylate synthase inhibitors for non-small cell lung cancer
- (2011) Elena Galvani et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Prospective Molecular Marker Analyses ofEGFRandKRASFrom a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
- (2011) Wolfram Brugger et al. JOURNAL OF CLINICAL ONCOLOGY
- AKT1 polymorphisms and survival of early stage non-small cell lung cancer
- (2011) Min Jung Kim et al. JOURNAL OF SURGICAL ONCOLOGY
- Genome-Wide Association Study of Survival in Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy
- (2011) Xifeng Wu et al. JNCI-Journal of the National Cancer Institute
- Tumour evolution inferred by single-cell sequencing
- (2011) Nicholas Navin et al. NATURE
- Impact ofABCG2polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients
- (2011) Clara Lemos et al. PHARMACOGENOMICS
- Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data
- (2011) Fredrik Nyberg et al. PHARMACOGENOMICS
- Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma
- (2010) Andrey Frolov et al. AMERICAN JOURNAL OF SURGERY
- Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib
- (2010) E. Giovannetti et al. MOLECULAR CANCER THERAPEUTICS
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- (2009) Jorg Hartmann et al. CURRENT DRUG METABOLISM
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- (2009) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy
- (2009) Michelle A.T. Hildebrandt et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib
- (2009) Fei Ma et al. LUNG CANCER
- Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers
- (2009) Marcello Tiseo et al. LUNG CANCER
- Sequencing technologies — the next generation
- (2009) Michael L. Metzker NATURE REVIEWS GENETICS
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
- (2008) M S Kim et al. BRITISH JOURNAL OF CANCER
- Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
- (2008) C Lemos et al. BRITISH JOURNAL OF CANCER
- Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity
- (2008) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer
- (2008) Marcello Tiseo et al. Journal of Thoracic Oncology
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
- EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
- (2008) Chin-Lun Huang et al. LUNG CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now